The effect of combination therapy of inhaled corticosteroids and long-acting beta2-agonists on acute exacerbation in moderate to severe COPD patients

Hye Cheol Jeong, Eun Sil Ha, Jin Yong Jung, Kyung Ju Lee, Seung Heon Lee, Se Joong Kim, Eun Joo Lee, Gyu Young Hur, Sung Yong Lee, Je Hyeong Kim, Sang Yeub Lee, Chol Shin, Jae Jeong Shim, Kwang Ho In, Kyung Ho Kang, Se Hwa Yoo

Research output: Contribution to journalArticle

Abstract

Background: The role of combination therapy of inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) in asthma is well established, but nor much is known about this treatment in COPD. Recent studies have revealed that combining therapy is associated with fewer acute exacerbations in COPD, but in most of the studies, high-dose combination therapies have been employed. The current study assessed the effect of moderate or high dose combination therapy of ICS plus LABA on the frequency of acute exacerbations in COPD. Methods: Between January 1, 2001 and August 31, 2004, 46 patients with COPD (moderate, severe, very severe) were enrolled who received either fluticasone/salmeterol (flu/sal) 250μg /50μg twice a day (group A) or flu/sal 500μg /50μg twice a day (group B) for more than a year. We divided them into two groups depending on the dosage of ICS plus LABA Effect of drugs was compared based on the factors such as symptom aggravation, number of admission, and time to first exacerbation during a year after use. Results: Eleven of twenty six patients in group A (42.3%) experienced acute exacerbation and eleven of twenty patients in group B (55%) experienced acute exacerbation during 1 year. Mean exacerbation rate of Group A was 0.96 and Group B was 1.05. Mean admission rate was 0.15 and 0.30, respectively. There was no statistically significant difference of aggravation rate, number of administration and time to first exacerbation between the two treatment groups. Conclusion: There was no significant difference between moderate and high dose combined inhaler therapy to reduce acute exacerbation in COPD patients (moderate, severe, very severe). Hence, the effective dose of combination therapy needs further study in patients with COPD.

Original languageEnglish
Pages (from-to)164-169
Number of pages6
JournalTuberculosis and Respiratory Diseases
Volume59
Issue number2
Publication statusPublished - 2005 Sep 1

Fingerprint

Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Therapeutics
Nebulizers and Vaporizers
Asthma
Pharmaceutical Preparations

Keywords

  • Acute exacerbation
  • COPD
  • Inhaled corticosteroids
  • Long acting β-agonist

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{27b7b85c05994823a64f8ce2942bbe54,
title = "The effect of combination therapy of inhaled corticosteroids and long-acting beta2-agonists on acute exacerbation in moderate to severe COPD patients",
abstract = "Background: The role of combination therapy of inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) in asthma is well established, but nor much is known about this treatment in COPD. Recent studies have revealed that combining therapy is associated with fewer acute exacerbations in COPD, but in most of the studies, high-dose combination therapies have been employed. The current study assessed the effect of moderate or high dose combination therapy of ICS plus LABA on the frequency of acute exacerbations in COPD. Methods: Between January 1, 2001 and August 31, 2004, 46 patients with COPD (moderate, severe, very severe) were enrolled who received either fluticasone/salmeterol (flu/sal) 250μg /50μg twice a day (group A) or flu/sal 500μg /50μg twice a day (group B) for more than a year. We divided them into two groups depending on the dosage of ICS plus LABA Effect of drugs was compared based on the factors such as symptom aggravation, number of admission, and time to first exacerbation during a year after use. Results: Eleven of twenty six patients in group A (42.3{\%}) experienced acute exacerbation and eleven of twenty patients in group B (55{\%}) experienced acute exacerbation during 1 year. Mean exacerbation rate of Group A was 0.96 and Group B was 1.05. Mean admission rate was 0.15 and 0.30, respectively. There was no statistically significant difference of aggravation rate, number of administration and time to first exacerbation between the two treatment groups. Conclusion: There was no significant difference between moderate and high dose combined inhaler therapy to reduce acute exacerbation in COPD patients (moderate, severe, very severe). Hence, the effective dose of combination therapy needs further study in patients with COPD.",
keywords = "Acute exacerbation, COPD, Inhaled corticosteroids, Long acting β-agonist",
author = "Jeong, {Hye Cheol} and Ha, {Eun Sil} and Jung, {Jin Yong} and Lee, {Kyung Ju} and Lee, {Seung Heon} and Kim, {Se Joong} and Lee, {Eun Joo} and Hur, {Gyu Young} and Lee, {Sung Yong} and Kim, {Je Hyeong} and Lee, {Sang Yeub} and Chol Shin and Shim, {Jae Jeong} and In, {Kwang Ho} and Kang, {Kyung Ho} and Yoo, {Se Hwa}",
year = "2005",
month = "9",
day = "1",
language = "English",
volume = "59",
pages = "164--169",
journal = "Tuberculosis and Respiratory Diseases",
issn = "1738-3536",
publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",
number = "2",

}

TY - JOUR

T1 - The effect of combination therapy of inhaled corticosteroids and long-acting beta2-agonists on acute exacerbation in moderate to severe COPD patients

AU - Jeong, Hye Cheol

AU - Ha, Eun Sil

AU - Jung, Jin Yong

AU - Lee, Kyung Ju

AU - Lee, Seung Heon

AU - Kim, Se Joong

AU - Lee, Eun Joo

AU - Hur, Gyu Young

AU - Lee, Sung Yong

AU - Kim, Je Hyeong

AU - Lee, Sang Yeub

AU - Shin, Chol

AU - Shim, Jae Jeong

AU - In, Kwang Ho

AU - Kang, Kyung Ho

AU - Yoo, Se Hwa

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Background: The role of combination therapy of inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) in asthma is well established, but nor much is known about this treatment in COPD. Recent studies have revealed that combining therapy is associated with fewer acute exacerbations in COPD, but in most of the studies, high-dose combination therapies have been employed. The current study assessed the effect of moderate or high dose combination therapy of ICS plus LABA on the frequency of acute exacerbations in COPD. Methods: Between January 1, 2001 and August 31, 2004, 46 patients with COPD (moderate, severe, very severe) were enrolled who received either fluticasone/salmeterol (flu/sal) 250μg /50μg twice a day (group A) or flu/sal 500μg /50μg twice a day (group B) for more than a year. We divided them into two groups depending on the dosage of ICS plus LABA Effect of drugs was compared based on the factors such as symptom aggravation, number of admission, and time to first exacerbation during a year after use. Results: Eleven of twenty six patients in group A (42.3%) experienced acute exacerbation and eleven of twenty patients in group B (55%) experienced acute exacerbation during 1 year. Mean exacerbation rate of Group A was 0.96 and Group B was 1.05. Mean admission rate was 0.15 and 0.30, respectively. There was no statistically significant difference of aggravation rate, number of administration and time to first exacerbation between the two treatment groups. Conclusion: There was no significant difference between moderate and high dose combined inhaler therapy to reduce acute exacerbation in COPD patients (moderate, severe, very severe). Hence, the effective dose of combination therapy needs further study in patients with COPD.

AB - Background: The role of combination therapy of inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) in asthma is well established, but nor much is known about this treatment in COPD. Recent studies have revealed that combining therapy is associated with fewer acute exacerbations in COPD, but in most of the studies, high-dose combination therapies have been employed. The current study assessed the effect of moderate or high dose combination therapy of ICS plus LABA on the frequency of acute exacerbations in COPD. Methods: Between January 1, 2001 and August 31, 2004, 46 patients with COPD (moderate, severe, very severe) were enrolled who received either fluticasone/salmeterol (flu/sal) 250μg /50μg twice a day (group A) or flu/sal 500μg /50μg twice a day (group B) for more than a year. We divided them into two groups depending on the dosage of ICS plus LABA Effect of drugs was compared based on the factors such as symptom aggravation, number of admission, and time to first exacerbation during a year after use. Results: Eleven of twenty six patients in group A (42.3%) experienced acute exacerbation and eleven of twenty patients in group B (55%) experienced acute exacerbation during 1 year. Mean exacerbation rate of Group A was 0.96 and Group B was 1.05. Mean admission rate was 0.15 and 0.30, respectively. There was no statistically significant difference of aggravation rate, number of administration and time to first exacerbation between the two treatment groups. Conclusion: There was no significant difference between moderate and high dose combined inhaler therapy to reduce acute exacerbation in COPD patients (moderate, severe, very severe). Hence, the effective dose of combination therapy needs further study in patients with COPD.

KW - Acute exacerbation

KW - COPD

KW - Inhaled corticosteroids

KW - Long acting β-agonist

UR - http://www.scopus.com/inward/record.url?scp=27644534553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644534553&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 164

EP - 169

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

SN - 1738-3536

IS - 2

ER -